{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T21:08:25Z","timestamp":1774732105810,"version":"3.50.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011944","name":"School of Public Health, University of California Berkeley","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011944","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011096","name":"Jazz Pharmaceuticals plc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Sleep Medicine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.sleep.2023.05.023","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T06:12:53Z","timestamp":1687155173000},"page":"65-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study"],"prefix":"10.1016","volume":"109","author":[{"given":"Charles J.","family":"Bae","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phyllis C.","family":"Zee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eileen B.","family":"Leary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas S.","family":"Fuller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wayne","family":"Macfadden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Candler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa L.","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aatif M.","family":"Husain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sleep.2023.05.023_bib1","volume":"3","author":"Kornum","year":"2017","journal-title":"Narcolepsy. Nat Rev Dis Primers"},{"key":"10.1016\/j.sleep.2023.05.023_bib2","series-title":"The international classification of sleep disorders","year":"2014"},{"key":"10.1016\/j.sleep.2023.05.023_bib3","series-title":"The international classification of sleep disorders","year":"2014"},{"key":"10.1016\/j.sleep.2023.05.023_bib4","series-title":"Xyrem\u00ae (sodium oxybate) oral solution, CIII [prescribing information]","year":"2022"},{"issue":"19","key":"10.1016\/j.sleep.2023.05.023_bib5","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1056\/NEJM199511093331917","article-title":"Declaring the sodium content of drug products","volume":"333","author":"Szarfman","year":"1995","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.sleep.2023.05.023_bib6","author":"US Food and Drug Administration"},{"key":"10.1016\/j.sleep.2023.05.023_bib7","author":"US Food and Drug Administration"},{"issue":"6","key":"10.1016\/j.sleep.2023.05.023_bib8","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1111\/cts.13087","article-title":"Pharmacokinetics, bioavailability, and bioequivalence of lower-sodium oxybate in healthy participants in 2 open-label, randomized, crossover studies","volume":"14","author":"Chen","year":"2021","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.sleep.2023.05.023_bib9","series-title":"Xywav\u00ae (calcium, magnesium, potassium, and sodium oxybates) oral solution, CIII [prescribing information]","year":"2022"},{"key":"10.1016\/j.sleep.2023.05.023_bib10","series-title":"Clinical superiority findings","year":"2021"},{"issue":"3","key":"10.1016\/j.sleep.2023.05.023_bib11","doi-asserted-by":"crossref","first-page":"zsaa206","DOI":"10.1093\/sleep\/zsaa206","article-title":"Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy","volume":"44","author":"Bogan","year":"2021","journal-title":"Sleep"},{"issue":"suppl 1","key":"10.1016\/j.sleep.2023.05.023_bib12","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1007\/s12070-014-0722-6","article-title":"Does AHI value enough for evaluating the obstructive sleep apnea severity?","volume":"67","author":"D\u00fcndar","year":"2015","journal-title":"Indian J Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.sleep.2023.05.023_bib13","article-title":"Epworth sleepiness scale is associated with hypothyroidism in male patients with obstructive sleep apnea","volume":"13","author":"Wang","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.sleep.2023.05.023_bib14","author":"About the"},{"issue":"6","key":"10.1016\/j.sleep.2023.05.023_bib15","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A\u00a0new method for measuring daytime sleepiness: the Epworth Sleepiness Scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep"},{"issue":"7","key":"10.1016\/j.sleep.2023.05.023_bib16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/sleep\/32.7.915","article-title":"Development of the FOSQ-10: a short version of the functional outcomes of sleep questionnaire","volume":"32","author":"Chasens","year":"2009","journal-title":"Sleep"},{"issue":"2","key":"10.1016\/j.sleep.2023.05.023_bib17","first-page":"135","article-title":"Rapid screening for perceived cognitive impairment in major depressive disorder","volume":"25","author":"Iverson","year":"2013","journal-title":"Ann Clin Psychiatr"},{"key":"10.1016\/j.sleep.2023.05.023_bib18","series-title":"Guideline: sodium intake for adults and children","author":"World Health Organization","year":"2012"},{"key":"10.1016\/j.sleep.2023.05.023_bib19","series-title":"Department of agriculture. 2015-2020 dietary guidelines for Americans","year":"2015"},{"key":"10.1016\/j.sleep.2023.05.023_bib20","author":"US Food and Drug Administration"},{"key":"10.1016\/j.sleep.2023.05.023_bib21","series-title":"Dietary reference intakes for sodium and potassium","year":"2019"},{"issue":"7","key":"10.1016\/j.sleep.2023.05.023_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00228-015-1855-6","article-title":"Cytochrome P450 2D6 genotype affects the pharmacokinetics of controlled-release paroxetine in healthy Chinese subjects: comparison of traditional phenotype and activity score systems","volume":"71","author":"Chen","year":"2015","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.sleep.2023.05.023_bib23","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.sleep.2021.06.008","article-title":"The Nexus Narcolepsy Registry: methodology, study population characteristics, and patterns and predictors of narcolepsy diagnosis","volume":"84","author":"Ohayon","year":"2021","journal-title":"Sleep Med"},{"issue":"9","key":"10.1016\/j.sleep.2023.05.023_bib24","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.5664\/jcsm.9326","article-title":"Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment","volume":"17","author":"Maski","year":"2021","journal-title":"J\u00a0Clin Sleep Med"},{"issue":"suppl 2","key":"10.1016\/j.sleep.2023.05.023_bib25","doi-asserted-by":"crossref","first-page":"A198","DOI":"10.1093\/sleep\/zsab072.502","article-title":"Cardio-vascular burden of narcolepsy disease (CV-BOND): a real-world evidence study [abstract 503]","volume":"44","author":"Ben-Joseph","year":"2021","journal-title":"Sleep"},{"key":"10.1016\/j.sleep.2023.05.023_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.sleep.2016.04.004","article-title":"Medical comorbidity in narcolepsy: findings from the Burden of Narcolepsy Disease (BOND) study","volume":"33","author":"Black","year":"2017","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2023.05.023_bib27","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.sleep.2017.11.1125","article-title":"Comorbidities in a community sample of narcolepsy","volume":"43","author":"Cohen","year":"2018","journal-title":"Sleep Med"},{"key":"10.1016\/j.sleep.2023.05.023_bib28","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s40263-022-00926-0","article-title":"Changes in cataplexy frequency in a clinical trial of lower-sodium oxybate with taper and discontinuation of other anticataplectic medications","volume":"36","author":"Dauvilliers","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.sleep.2023.05.023_bib29","unstructured":"Ben-Joseph RH, Somers VK, Black J, et\u00a0al. Hypertension onset among narcolepsy patients newly treated with sodium oxybate [poster 344]. Annual meeting of the associated professional sleep societies. Charlotte, NC2022."},{"issue":"7599","key":"10.1016\/j.sleep.2023.05.023_bib30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/bmj.39147.604896.55","article-title":"Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP)","volume":"334","author":"Cook","year":"2007","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.sleep.2023.05.023_bib31","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1056\/NEJMoa2105675","article-title":"Effect of salt substitution on cardiovascular events and death","volume":"385","author":"Neal","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.sleep.2023.05.023_bib32","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1056\/NEJM200101043440101","article-title":"Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research group","volume":"344","author":"Sacks","year":"2001","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.sleep.2023.05.023_bib33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/pds.1701","article-title":"Blood pressure reduction in hypertensive patients after withdrawal of effervescent medication","volume":"18","author":"Ubeda","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"10.1016\/j.sleep.2023.05.023_bib34","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1097\/HJH.0000000000001733","article-title":"Effect of effervescent paracetamol on blood pressure: a crossover randomized clinical trial","volume":"36","author":"Benitez-Camps","year":"2018","journal-title":"J\u00a0Hypertens"},{"issue":"18","key":"10.1016\/j.sleep.2023.05.023_bib35","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/eurheartj\/ehac059","article-title":"Sodium-containing acetaminophen and cardiovascular outcomes in individuals with and without hypertension","volume":"43","author":"Zeng","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.sleep.2023.05.023_bib36","series-title":"Clinical guidelines on the identification, evaluation, and treatments of overweight and obesity in adults: the evidence report","year":"1998"},{"issue":"7","key":"10.1016\/j.sleep.2023.05.023_bib37","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S2352-4642(18)30133-0","article-title":"Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation","volume":"2","author":"Plazzi","year":"2018","journal-title":"Lancet Child Adolesc Health"},{"issue":"6","key":"10.1016\/j.sleep.2023.05.023_bib38","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.sleep.2008.05.012","article-title":"Weight loss in narcolepsy patients treated with sodium oxybate","volume":"10","author":"Husain","year":"2009","journal-title":"Sleep Med"},{"issue":"7","key":"10.1016\/j.sleep.2023.05.023_bib39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/sleep\/zsaa295","article-title":"BMI changes in pediatric type 1 narcolepsy under sodium oxybate treatment","volume":"44","author":"Ponziani","year":"2021","journal-title":"Sleep"},{"issue":"3","key":"10.1016\/j.sleep.2023.05.023_bib40","doi-asserted-by":"crossref","DOI":"10.1111\/jsr.12684","article-title":"Decreased body mass index during treatment with sodium oxybate in narcolepsy type 1","volume":"28","author":"Schinkelshoek","year":"2019","journal-title":"J\u00a0Sleep Res"},{"issue":"11","key":"10.1016\/j.sleep.2023.05.023_bib41","first-page":"2111","article-title":"Treatment of edema","volume":"71","author":"O'Brien","year":"2005","journal-title":"Am Fam Physician"}],"updated-by":[{"DOI":"10.1016\/j.sleep.2024.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000}}],"container-title":["Sleep Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945723001922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1389945723001922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,19]],"date-time":"2024-04-19T00:40:18Z","timestamp":1713487218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1389945723001922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":41,"alternative-id":["S1389945723001922"],"URL":"https:\/\/doi.org\/10.1016\/j.sleep.2023.05.023","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.sleep.2024.04.001","asserted-by":"object"}]},"ISSN":["1389-9457"],"issn-type":[{"value":"1389-9457","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and tolerability in people with narcolepsy transitioning from sodium oxybate to low-sodium oxybate: Data from the real-world TENOR study","name":"articletitle","label":"Article Title"},{"value":"Sleep Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sleep.2023.05.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}